:: Volume 8, Issue 3 (9-2019) ::
Int J Med Invest 2019, 8(3): 47-54 Back to browse issues page
An Investigation In To the Effect of Buprenorphine Tablet on Drug Rehabilitation Clinics in Tabriz
Farhad Hassan Zadeh *
Master Of Supervision On Medicine Affairs, Faculty Of Fundamental Sciences, Islamic Azad University, Ahar Branch, Ahar, Iran
Abstract:   (1286 Views)
Introduction: One of the typical ways of drug rehabilitation in Iran is the usage of Buprenorphine tablets in drug rehabilitation clinics under the supervision of Practitioner. As the Buprenorphine acts as partial agonists in opioid receptors of the body, thus this medicine is used as the preservative in the dependence on opioid substances and leads to the elimination of the symptoms of drug rehabilitation among people giving up the substances. The aim of this study is to examine the effect of Buprenorphine among the addicted people to opium with daily usage of less than 3 grams in drug rehabilitation clinics in Tabriz.
Methods: This research is carried out as a field study in ten top drug rehabilitation clinics according to the protocol of Tabriz University of medical science. Among existing files in clinics, people with daily opium usage of 3 grams or less were investigated. Patients’ information was collected using questionnaires containing nineteen (19) items and analyzed by SPSS software version 19.
Findings: Findings indicate that the age range of (30 to 40) and harsh job situation increase the risk of addiction to opium. No evidence of giving up opium usage in replacement of Buprenorphine was observed. Factors like marital status and smoking are among the risk factors of tendency towards drug.
Conclusion: It seems that Buprenorphine tablets with dosage of 4 mg on daily basis are effective among opium-addicted people with less than 3 grams and could lead to eliminate the giving up symptoms and success of the treatment. As a preservative treatment, it also leads to more stability and coherence in the families and makes the people return to their jobs and society as well.
Keywords: Addiction, Opium, Buprenorphine
Full-Text [PDF 385 kb]   (268 Downloads)    
Type of Study: Research | Subject: General
1. 1. Meldon, K., Anita, S., Alice, O. & Sharon, C.” Buprenorphine: New treatment of opioid addiction in primary care. Can Fam Physician”, March; 57(3): 281–289, 2011. 2. Michael, A., Yokell, N., Zaller, D., Traci, C. & Green, J.D. :Rich. Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International ReviewCurr Drug Abuse Rev:. Author manuscript; available in PMC August 11, 2011. 3. Chapleo, C.B. & Crossley, D.I. “Buprenorphine therapies for the treatment of opioid dependence-subutex and sorboxone”, 2002. 4. Finn, A.K. & Whistler, J.L. “Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal Neuron”, 32, pp. 829–839, 2001. 5. Ford, C., Morton, S., Lintzeris, N., Bury, J. & Gerada, C. “Guidance for the Use of Buprenorphine for the Treatment of Opioid Dependence in Primary Care”, 2004. 6. Kress, H.G. "Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine". Eur J Pain 13 (3): 219–30, 2009. 7. Jennifer, P.R., Marek, Ch., Mahmud, M. & Richard, S. “Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in MalaysiaPLoS One”; 7(12) , 2012. 8. Kotz M, Clark M, Compton P, et al. Dept. HHS, editor. Managing chronic pain in adults with or in recovery from substance use disorders: A treatment improvement protocol TIP 54. Rockville, MD: SAMHSA; 2012. 9. Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012;1248:124–39. 10. Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27:669–76. 11. Neumann AM, Blondell RD, Jaanimagi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32:68–78. 12. Rosen K, Gutierrez A, Haller D, Potter JS. Sublingual Buprenorphine for Chronic Pain: A Survey of Clinician Prescribing Practices. Clin J Pain. 2013 Epub ahead of print. 13. Roux P, Sullivan M, Cohen J, Fugon L, Jones J, Vosburg S, Cooper Z, Manubay J, Mogali S, Comer S. Buprenorphine-naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain. 2013;154:1442–8.

XML     Print

Volume 8, Issue 3 (9-2019) Back to browse issues page